Overview

Safety Study of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome

Status:
Completed

Trial end date:
2013-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and pharmacokinetics of TTI-1612 in women with interstitial cystitis/bladder pain syndrome.

Phase:

Phase 1

Details

Lead Sponsor:

Trillium Therapeutics Inc.